MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Other Events

ME Staff 8-k
-
0
MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Other Events

MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Other Events
Item 8.01 Other Events.

On June 14, 2019, MiMedx Group, Inc. (the “Company”) issued a press release urging shareholders of the Company to vote for the Company’s three director nominees, K. Todd Newton, Dr. Kathleen Behrens Wilsey and Timothy R. Wright, for election at the Company’s 2018 annual meeting of shareholders to be held on June 17, 2019. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1    Press release of MiMedx Group, Inc., dated June 14, 2019.

2


MIMEDX GROUP, INC. Exhibit
EX-99.1 2 d765454dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   MiMedx Urges Shareholders to Vote Today “FOR” All of the Board’s Highly Qualified Nominees on the BLUE Proxy Card The MiMedx Annual Meeting is This Coming Monday,…
To view the full exhibit click here

About MIMEDX GROUP, INC. (NASDAQ:MDXG)

MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.